Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more
Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.06 Billion CNY
Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has total liabilities worth CN¥2.06 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hainan Huluwa Pharmaceutical Group Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Fangda Group Co Ltd
SHE:200055
|
China | HK$6.98 Billion |
|
Golden Flower Tbk PT
JK:POLU
|
Indonesia | Rp82.15 Billion |
|
Gaotu Techedu Inc
F:18WA
|
Germany | €3.70 Billion |
|
Sarawak Oil Palms Bhd
KLSE:5126
|
Malaysia | RM1.28 Billion |
|
Hefei Snowky Elec Co Ltd
SHE:001387
|
China | CN¥1.13 Billion |
|
Zhejiang Huada New Materials Co Ltd
SHG:605158
|
China | CN¥5.93 Billion |
|
Hung Ching Development & Construction Co Ltd
TW:2527
|
Taiwan | NT$14.47 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Hainan Huluwa Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Huluwa Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2024)
The table below shows the annual total liabilities of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.22 Billion | +16.84% |
| 2023-12-31 | CN¥1.90 Billion | +46.61% |
| 2022-12-31 | CN¥1.30 Billion | +56.16% |
| 2021-12-31 | CN¥830.41 Million | +37.33% |
| 2020-12-31 | CN¥604.68 Million | +36.60% |
| 2019-12-31 | CN¥442.67 Million | -9.17% |
| 2018-12-31 | CN¥487.37 Million | +6.92% |
| 2017-12-31 | CN¥455.83 Million | +11.93% |
| 2016-12-31 | CN¥407.26 Million | -- |